Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.63B P/E - EPS this Y -3.10% Ern Qtrly Grth -
Income -184.13M Forward P/E -10.32 EPS next Y 48.50% 50D Avg Chg -
Sales 237k PEG -2.02 EPS past 5Y - 200D Avg Chg 18.00%
Dividend N/A Price/Book 4.99 EPS next 5Y 5.00% 52W High Chg -17.00%
Recommedations 1.50 Quick Ratio 3.10 Shares Outstanding 588.06M 52W Low Chg 64.00%
Insider Own 0.12% ROA -41.47% Shares Float 474.96M Beta 0.55
Inst Own 67.90% ROE -112.29% Shares Shorted/Prior 50.95M/43.57M Price 3.20
Gross Margin - Profit Margin - Avg. Volume 5,610,301 Target Price 5.08
Oper. Margin -236,039.14% Earnings Date May 9 Volume 2,355,788 Change -0.31%
About Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation News
03/21/24 Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
03/19/24 Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
03/15/24 Geron, Madrigal Pharmaceuticals jump on good news from FDA
03/15/24 Stocks to Watch Friday: Adobe, Ulta, Fisker
03/15/24 Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
03/14/24 Geron Stock Is Soaring After Hours: What's Going On?
03/14/24 Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
03/14/24 UPDATE 3-Geron's blood disorder drug gets FDA advisers' backing
03/13/24 Implied Volatility Surging for Geron (GERN) Stock Options
03/12/24 UPDATE 3-US FDA staff raises concerns on Geron's blood disorder drug
03/01/24 Geron Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
10:00 AM Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript
02/28/24 Geron (GERN) Q4 2023 Earnings Call Transcript
02/28/24 Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
02/22/24 Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/14/24 Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
01/12/24 Geron to Participate in the B. Riley Securities Virtual Oncology Conference
12/15/23 Geron (GERN) Upgraded to Buy: Here's Why
12/14/23 Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?
12/11/23 Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
GERN Chatroom

User Image telomerase Posted - 8 hours ago

$GERN if only Scarlett had actually STUDIED sharks, instead of just feeding his investors to them: https://www.researchgate.net/publication/379016677_RNA_analysis_of_the_longest_living_vertebrate_Greenland_shark_revealed_an_abundance_of_LINE-like_elements_in_its_transcriptome

User Image Fern64 Posted - 11 hours ago

$GERN https://www.onclive.com/view/imetelstat-shows-potential-to-transform-qol-in-lower-risk-mds

User Image crabbypatty31 Posted - 12 hours ago

$GERN Now that's a narrow trading range today for sure.

User Image Copperdust Posted - 12 hours ago

$GERN Tom Brady’s Trainers daughter just diagnosed with AML. Articles like this put the disease and the need for a cure or treatment front and center. https://www.foxnews.com/entertainment/celebrity-trainer-gunnar-peterson-shares-daughter-4-leukemia-life-changing-turn

User Image Sunset19 Posted - 15 hours ago

$GERN BORING

User Image aj_ Posted - 19 hours ago

$GERN whiner day 400. Sell.

User Image ZoeyTanner Posted - 21 hours ago

$GERN Nothing here, and never will be withchip

User Image YouVSYou Posted - 1 day ago

@YouVSYou $GERN $PXLW $FEMY DOJI candles on Watch for Reversals $AVTX $PRCH Top watches Tomorrow 💰 $17,500 Today in the 📚 Let’s finish March out Strong 💪

User Image KingCryptoMan Posted - 1 day ago

$GERN https://www.biotechtv.com/post/geron-march-26-2024 The whole video with Dr. Scarlett. Thanks to our friends over at Imetelchat.

User Image Nullify Posted - 1 day ago

$GERN bullish but makes me wonder if mm is going to bring it down.

User Image silversg3006 Posted - 1 day ago

$GERN Decent volume today!

User Image Mattedbumhair Posted - 1 day ago

$GERN Fda got to follow adcom ruling right??? Spry got majority adcom too but still got crl citing more data from the company. Any thoughts?

User Image share97 Posted - 1 day ago

$GERN it’s almost as if the institutions that bought at 3$ knew what they were doing

User Image silversg3006 Posted - 1 day ago

$GERN Nice rebound

User Image aj_ Posted - 1 day ago

$GERN the definition of a whiner. @WhineyTanner. All the posts, not some are a whine.

User Image ZoeyTanner Posted - 1 day ago

$GERN Wonderbar. Up .o2 let's party...sad

User Image patso1964 Posted - 1 day ago

$GERN

User Image finna_buy_more Posted - 1 day ago

$GERN imetelstat is forecasted to bring $1.8b of revenue by 2033. Source : https://www.pharmaceutical-technology.com/data-insights/imetelstat-sodium-geron-net-present-value/#:~:text=The%20revenue%20for%20Imetelstat%20Sodium,net%20present%20value%20(NPV).

User Image ShibaShibaShiba Posted - 1 day ago

$GERN Forward looking sentiment is great and all, but GERN is overvalued when you take into account that they have zero revenue and no sources of income besides 2 offerings in the past 13 months... Will they be worth something? Yes! Are they worth something right now? NO... Give it a year or 2 for their product to hit the market, advertising plan mapped out and implemented and for them to be bringing in a revenue, then it should have a price that will hold its share value. Until then, we'll have news release hype runs and bleed offs

User Image ZoeyTanner Posted - 1 day ago

$GERN Dead money

User Image cmbrewer89 Posted - 1 day ago

$GERN I see you’re still as terrible as you were 5 years ago. I had faith back then but just lost tons of money. Moved on and never looked back

User Image Akwaba76 Posted - 2 days ago

$GERN https://x.com/BiotechTVHQ/status/1772747985253978169?t=6cqib1MRzfDC09xcaMQOxw&s=09

User Image ThelmaBarnes Posted - 2 days ago

$GERN Gain insights into potential market movements as experts share their predictions for the week ahead

User Image SilverBack83 Posted - 2 days ago

@aku78 my problem with people pumping MAIA is that it absolutely lacks any and all safety data not to mention phase 2 is the first time the company is focusing on understanding how it interacts and potentially reacts to checkpoint inhibitors. This for me makes it a lotto play with a large chance of potential failure due to lack of safety being achieved. $ICU is a bit of an unknown for me given that it’s a holding company for a bunch of other stuff. It’s again a lotto play for me, but it might actually have a lower risk when compared to $MAIA. Of course, if MAIA turns out to be safe and effective, you could be looking at a 9 to 12 banger. As far as $GERN goes, they are the only company doing what they are doing, and own the patents, and have now shown real safety metrics and effectiveness. I plan to hold for another 16 to 24 months to see what the real value of the stock will be once they either get license, acquired, or deliver a commercial drug. $ 8-9, $15-18, and $? respectively

User Image Theshermank Posted - 2 days ago

$GERN Fda approval should have a 0.5 to 1$ bump is sp

User Image SilverBack83 Posted - 2 days ago

$GERN $MAIA fuck off with your useless spamming. $MAIA Can pound sand with its lame ass spammers. Know the difference and fuckoff

User Image Fern64 Posted - 2 days ago

$GERN https://www.targetedonc.com/view/zeidan-discusses-imetelstat-for-lower-risk-mds

User Image Radmanx Posted - 2 days ago

$GERN The last of the shorts remain! Let’s see how the next few weeks go.

User Image finna_buy_more Posted - 2 days ago

$GERN man, this thing is WAAAYYYY overvalued

User Image Peak_Big Posted - 2 days ago

$GERN shorts are fighting hard

Analyst Ratings
Needham Buy Mar 15, 24
Goldman Sachs Buy Mar 15, 24
Wedbush Outperform Mar 15, 24
Needham Buy Mar 13, 24
Needham Buy Mar 12, 24
Needham Buy Mar 4, 24
Needham Buy Feb 28, 24
Goldman Sachs Buy Sep 12, 23
Wedbush Outperform Aug 29, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
O'Farrell Elizabeth G. Director Director Aug 24 Buy 2.28 13,186 30,064 26,220 08/24/23
LAWLIS V BRYAN Director Director May 11 Sell 3 35,000 105,000 05/11/23
LAWLIS V BRYAN Director Director May 11 Option 1.1 35,000 38,500 35,000 05/11/23
Molineaux Susan Director Director May 01 Sell 2.48 35,000 86,800 05/01/23
Molineaux Susan Director Director May 01 Option 1.1 35,000 38,500 35,000 05/01/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Feb 09 Sell 3.03 384,719 1,165,699 02/10/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Feb 09 Option 1.51 150,000 226,500 384,719 02/10/23
Bloom Olivia Kyusuk EVP, Chief Financial.. EVP, Chief Financial Officer Feb 08 Sell 3.08 400,000 1,232,000 74,588 02/10/23
Bloom Olivia Kyusuk EVP, Chief Financial.. EVP, Chief Financial Officer Feb 08 Option 1.51 400,000 604,000 474,588 02/10/23
SCARLETT JOHN A Chairman, President.. Chairman, President and CEO Feb 08 Sell 3.04 1,340,000 4,073,600 02/10/23
SCARLETT JOHN A Chairman, President.. Chairman, President and CEO Feb 08 Option 1.5 1,340,000 2,010,000 446,668 02/10/23
EASTHAM KARIN Director Director Jan 13 Option 1.10 35,000 38,500 109,047 01/17/23
GRETHLEIN ANDREW J EVP, Chief Operating.. EVP, Chief Operating Officer Sep 12 Option 1.7 234,719 399,022 234,719 09/14/22
EASTHAM KARIN Director Director Apr 20 Option 1.41 35,000 49,350 74,047 04/21/22